The advent of ATTR-specific drugs, though pricey, is enabling better survival in these overlapping diseases, researchers say.

Life Molecular Imaging GmbH (LMI) announces today that florbetaben (18F) has been granted orphan designation by the European Commission for the diagnosis of Transthyretin (ATTR) ...

Aortic valve narrowing (aortic stenosis) with concomitant cardiac amyloidosis is a severe heart disease of old age that is ...

However, few medicines are approved for ATTR-wt. GlobalData estimates that vutrisiran’s entrance into the ATTR-wt market will ...

Florbetaben (18F) has been granted Orphan drug designation for the diagnosis of ATTR amyloidosisFlorbetaben (18F) previously received orphan drug designation as a diagnostic agent for the management ...

Heart failure often follows heart attacks, diabetes, or high blood pressure. However, a very different cause is being ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 13 Biotech Stocks with Huge Upside Potential. It declared on June 9 ...

− First and Only RNAi Therapeutic Approved by the European Commission for the Treatment of Wild-Type or Hereditary ATTR Amyloidosis with Cardiomyopathy – − Novel RNAi Mechanism Delivers ...

Jill White, Certified Life and Business Coach, international speaker, and founder of Overflow Coaching, is proud to announce ...

Keymed Biosciences Inc. (HKEX: 02162) today announced that Prof. Jun Shi's research team from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of ...

Ratings for Alnylam Pharmaceuticals ALNY -1.28% Get Free Report were provided by 18 analysts in the past three months, ...